Smartnuclide Biopharma
Clinical trials sponsored by Smartnuclide Biopharma, explained in plain language.
-
Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in first human test
Disease control Recruiting nowThis early-phase study tests a new radioactive drug (177Lu-DOTA-SNA040) in 12 people with advanced stomach, pancreatic, or bile duct cancers that have a specific marker (Claudin 18.2) and have stopped responding to standard treatments. The main goals are to check safety, find the…
Phase: EARLY_PHASE1 • Sponsor: SmartNuclide Biopharma • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New contrast agent could sharpen pancreatic cancer scans
Diagnosis Recruiting nowThis early-phase study tests a new contrast agent (68Ga-labelled claudin 18.2) used with PET/CT scans to better see pancreatic cancer. About 12 adults with pancreatic cancer will receive the agent to check its safety and how well it targets tumors. The goal is to improve cancer i…
Phase: EARLY_PHASE1 • Sponsor: SmartNuclide Biopharma • Aim: Diagnosis
Last updated May 26, 2026 05:45 UTC